Cue Biopharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 20.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 151.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Details
| Name | Cue Biopharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 29 |
| Founded | 2014 |
| Ipo Date | 2018-01-02 |
| Ceo | Shao-Lee Lin |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US22978P2056 |
| Cusip | 22978P205 |
| Cik | 0001645460 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | President, Chief Executive Officer and Director |
| Lucinda Warren | Principal Accounting Officer and Chief Business Officer |
| Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| James M. Ahlers | Chief Financial Officer |
| Agnes Lee | Chief Officer of Public and Investor Relations |
| Sumita Ray J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Contact
| Address | 40 Guest Street, Boston, Massachusetts 02135, United States |
| Phone | 617 949 2680 |
| Website | https://www.cuebiopharma.com |